TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

類似資料

• Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
  著者:: Zucali, P.A., 等
  出版事項: (2008)
• MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
  著者:: Presutti, Dario, 等
  出版事項: (2015)
• AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
  著者:: Choi, Yun Jung, 等
  出版事項: (2015)
• MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
  著者:: Wang, Qiming, 等
  出版事項: (2019)
• Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
  著者:: Yamaoka, Toshimitsu, 等
  出版事項: (2017)